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ABSTRACT: A detailed comprehensive study on how the
formation of soluble and insoluble carbamazepine/cyclodextrins
(CBZ/CD) complexes (with consequent changes in the solid-
phase composition) depends on the CD structure is not yet
available. Moreover, the study of possible influence of this drug
on the tendency of CDs and their complexes to self-aggregate is
still lacking. Phase-solubility studies demonstrated that CDs and
CBZ form a range of soluble (AL-type: αCD, βCD, and
hydroxypropylated CDs) and insoluble (BS-type: γCD)
complexes depending on CD used. HPβCD proved to be the
best CD solubilizer for CBZ forming the most stable complex
with highest apparent solubility, whereas γCD was shown to be
the best native CD. For the native CDs, CBZ solubilization
increases with increasing CD cavity diameter (αCD ≪ βCD <
γCD). Solid phases collected from phase-solubility studies were characterized by Fourier-transformed infrared spectroscopy,
differential scanning calorimetry, and X-ray powder diffraction to elucidate their composition and crystalline structure. They
provided similar conclusions being overall supportive of phase-solubility, osmolality, and permeation studies results. Solid CBZ
was the only detected component for AL-type profiles over the CD concentration range studied, whereas precipitation of poorly
soluble CBZ/γCD complexes (BS-type) was observed (i.e., at and beyond plateau region). Osmometry and permeation studies
were applied to evaluate the effect of CBZ on the aggregate formation and also to elucidate their influence on CD complex
solubility and permeation profile. Permeation method was shown to be the most effective method to detect and evaluate
aggregate formation in aqueous γCD and HPβCD solutions containing CBZ. CBZ did not affect the HPβCD tendency to self-
aggregate but CBZ did modify the aggregation behavior of γCD decreasing the apparent critical aggregation concentration value
from 4.2% (w/v) (in pure aqueous γCD solution) to 2.5% (w/v) (when CBZ was present).
1. INTRODUCTION
Carbamazepine (CBZ), 5H-dibenz[b,f ]azepine-5-carboxa-
mide, is the most widely used anticonvulsant drug for the
treatment of psychomotor epilepsy. Although effective, CBZ
constitutes a challenge for pharmaceutical formulators because
of its low water solubility (approximately <200 μg/mL), slow
dissolution rate, and polymorphism.1−5 Four different
anhydrous forms, and a dihydrate has been described in the
literature, where polymorph form I and form III are the most
frequently encountered.6−8
Although the different polymorphic forms of CBZ may
exhibit different dissolution rates and bioavailabilities, selection
of one polymorphic form over the others in a formulation may
not be a viable route for improving the bioavailability of the
drug. Other methods are needed to overcome the formulation
limitations of CBZ (polymorphism and poor dissolution rate),
one of which is the use of cyclodextrins (CD).9−13 These
pharmacopoeial approved excipients are very useful and used
in several commercialized products (pharmaceutical, chemical,
food, cosmetic, etc.) because of their safe toxicological profile
and ability to form water-soluble complexes.12,14−18
In aqueous media, CDs can form inclusion complexes with a
lipophilic molecule or part of a larger molecule or through
formation of noninclusion complexes.9,17,19 Solubilization of
drugs, through a micelle-like mechanism, may also occur
through formation of CD and/or drug/CD complex
aggregates.14,20 This ability of CDs to self-aggregate needs to
be controlled by pharmaceutical formulators, as it sometimes
needs to be prevented (can cause formulation instability
provoking therapeutical and economical losses) but may also
be advantageous for creation of novel drug delivery systems
because of its simplicity and versatility.12
Received: August 15, 2018
Accepted: December 13, 2018
Published: January 16, 2019
Article
http://pubs.acs.org/journal/acsodfCite This: ACS Omega 2019, 4, 1460−1469
© 2019 American Chemical Society 1460 DOI: 10.1021/acsomega.8b02045
ACS Omega 2019, 4, 1460−1469
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
D
ow
nl
oa
de
d 
vi
a 
A
A
L
B
O
R
G
 U
N
IV
 o
n 
A
ug
us
t 2
3,
 2
01
9 
at
 1
2:
30
:2
7 
(U
T
C
).
Se
e 
ht
tp
s:
//p
ub
s.
ac
s.
or
g/
sh
ar
in
gg
ui
de
lin
es
 f
or
 o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
is
he
d 
ar
tic
le
s.
Several studies of the interaction between CBZ and αCD,21
βCD,1−3,5,21−23 γCD,13 HPβCD,13,19,21,24−26 HEβCD,13
DMβCD,13 SBEβCD,4,27 and HPγCD13 have already been
published. However, a systematic, detailed, and comprehensive
study on the dependence of CD type on the formation of
soluble and insoluble complexes is not yet available. The
majority of the studies mentioned above utilize classic phase-
solubility studies to characterize the potential of different CD
types to increase the apparent solubility of CBZ by focusing on
the increase of CBZ concentration in solution dependent on
initial CD concentration. The composition and changes in
composition of the solid phase are, as for the majority of
studies on drug/CD complexes by phase-solubility experi-
ments, fully ignored. Moreover, changes in the composition of
the solid phase with respect to CD concentration as a
consequence of possible formation of poorly soluble CD/drug
complexes have also not been studied. Furthermore, none of
the previous publications on this topic have focused on and
described the possible influence of CBZ on the self-aggregation
behavior of these CDs and their complexes. The aim of the
present study is to provide a better understanding of the
interaction of CBZ with a range of relevant CDs (varying
cavity sizes: αCD, βCD, and γCD; and by comparing native
and hydroxypropylated CDs) on the basis of phase-solubility
studies including characterization of changes in the composi-
tion of the solid phase, changes in the concentration of CD in
solution as compared to the initial concentration, and the
formation of aggregates. To elucidate the composition and
crystalline structure of the solid phases, we have characterized
the solid phases obtained from the phase-solubility studies by
Fourier transform infrared spectroscopy (FTIR), differential
scanning calorimetry (DSC), and X-ray powder diffraction
(XRPD), some of which are reported in the Supporting
Information. The liquid phases were analyzed using perme-
ation and osmolality methods for the determination of the
influences of CBZ on the flux profile and apparent critical
aggregation concentration (cac) of the CDs.
2. RESULTS AND DISCUSSION
In the first part of this study, we attempt to correlate the type
of CBZ/CDs phase-solubility diagrams with the composition
of the obtained solid phases and elucidate the importance of
CD type on complexation and solubilization of these systems.
To get insight into the nature of the solid phase, we have used
diverse analytical techniques as previously mentioned. For
these tests, A-type phase-solubility profiles were tested at the
highest CD concentration used, whereas B-type phase-
solubility profiles were at least tested at two concentrations
(i.e., before and after the plateau region).
In the second part of this study, we aim to understand and
evaluate not only if/how CBZ can affect the flux and apparent
tendency of studied CDs to self-aggregate (comparing
apparent cac values) when associated in inclusion/non-
inclusion complexes but also how the CDs complexes
modulate CBZ permeability through a semi-permeable
membrane. This novel insight was mainly possible because of
the performance of osmometry and permeation studies.
Another novelty of this work compared with most publications
in this field (where presented graphs and values are based on
theoretical CD concentrations) was the use of Corona detector
that allowed us to quantify the actual concentration of CDs
and drug (simultaneously) present in liquid phases.
2.1. Phase-Solubility Studies. Usually the apparent water
solubility of drug is enhanced by the formation of drug/CD
complexes. To evaluate the interaction between CDs and CBZ,
phase-solubility diagrams were made by plotting the
concentration of CBZ brought into solution versus the actual
(as opposed to added) CD concentration (Figures 1 and 2).
Slopes were calculated by plotting all concentration range in
case of A-type diagrams or just using the initial linear portion
(for B-type diagrams). Using the apparent intrinsic solubility
(S0) of CBZ and determined slopes, we were able to determine
apparent stability constants (K1:1) and the complexation
efficiencies (CE). Also, the maximum increase (in percentage)
in apparent solubility of CBZ per mM of CD (IS) was
calculated (Table 1).
It has previously been described in the literature that native
CDs have low aqueous solubility compared with their
hydroxypropylated derivatives and that the native CDs are
more prone to self-assembly and aggregate formation. This
phenomenon can contribute for the definition of phase-
solubility profiles of many drugs.28,29
2.1.1. Native CDs. Hydroxypropylated CD derivatives (i.e.,
HPαCD, HPβCD, and HPγCD) are obtained by random
substitution that transforms the crystalline native CDs into
amorphous mixtures of large number of isomers.31,32 Thus,
HPαCD, HPβCD, and HPγCD and their complexes are unable
to form crystals in aqueous solutions and, because of their
enhanced solubility, generally display AL-type phase solubility
diagrams. On the other hand, native CDs and their complexes
Figure 1. Phase-solubility profile describing solubility of CBZ in
aqueous αCD, βCD, and γCD solutions at 25 °C. Symbols represent
mean ± SD (n = 3).
Figure 2. Obtained phase-solubility profiles for HP-CDs with CBZ
(25 °C). Symbols represent mean ± SD (n = 3).
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can form crystalline solid state and, thus, display limited
solubility in water that frequently leads to B-type phase-
solubility profiles. However, in case of CBZ, only γCD
presented the BS-type profile while αCD and βCD displayed
AL-type (Table 1). We believe that for βCD, the A-type phase-
solubility diagram is only observed because of the poor
solubility of βCD (high enough βCD concentrations to
observe BS-type diagrams are not possible to achieve).
Figure 1 shows the phase-solubility profile for native CDs
with CBZ. Combining the analysis of this figure with results of
Table 1, it is possible to see that αCD and CBZ did not have a
good interaction although it displayed AL phase-solubility
profile. K1:1 and CE values (8.9 M
−1 and 0.006, respectively)
are extremely small pointing to the fact that αCD cavity is too
small to host/interact with any part of CBZ.
As already mentioned, because of low aqueous solubility,
βCD displayed an AL phase-solubility profile with CBZ (Figure
1). Apparent solubility of formed complex increased linearly
with increasing βCD concentration. Complexation of CBZ by
βCD was possible and more effective when compared to αCD
as all parameters described in Table 1 increased significantly.
Generally, γCD displays BS-type profiles with guests and
CBZ was not an exception. In Figure 1, a typical BS-profile for
γCD with characteristic regions is presented: First, a linear
region, where the increase of CD concentration leads to the
formation of water-soluble CBZ/γCD complexes that,
consequently, increase CBZ total solubility. Thereafter a
plateau region, where the maximum CBZ solubility is achieved,
was expected. This region is not apparent from the data
obtained. Finally, the descendent part is achieved and it is
characterized by the decrease of apparent CBZ solubility due
to formation of insoluble CBZ/γCD complexes. This happens
because all the solid CBZ has been brought into solution or
precipitated as CD complex and that the increase in γCD
concentration will promote precipitation of the complex.
Overall, all calculated parameters presented in Table 1
(slope, K1:1, CE, and IS) increased with increasing CD cavity
size (αCD < βCD < γCD). Concerning the linear part of the
phase-solubility diagrams, γCD registered the highest value for
CE and IS of the native CDs showing that this was the native
CD that interacted the strongest (i.e., formed most stable
complex) and brought the most CBZ into solution.
All registered slopes were smaller than unity which suggests
the formation of simple 1:1 CBZ/native CD complexes in
accordance with literature.3,13,21,22,24
2.1.2. Hydroxypropylated Cyclodextrins. The phase-
solubility diagrams obtained for the hydroxypropylated CDs
(HP-CDs) also gave straight lines characteristic for AL-type
profiles (Figure 2).
These modified CDs were capable of solubilizing CBZ and
to increase its apparent solubility with increasing CD
concentration linearly. Similarly to αCD, HPαCD was also
the least efficient CD of this group to bring CBZ into solution.
The smaller cavity size probably hinders the interaction as
revealed by the calculated parameters (i.e., K1:1 = 31.4 M
−1; CE
= 0.022).
On the basis of calculated parameters (K1:1, CE, and IS), it is
possible to see that HPβCD was overall the best CD tested
because it formed the most stable complex and resulted in the
largest increase in CBZ solubility (Figure 2 and Table 1).
The observed slope values were smaller than unity, which is
an indication that complex formation follows a simple 1:1
stoichiometry also in the case of CBZ/HP-CD systems. Several
authors using phase-solubility studies in combination with
other analytical methods (e.g., FTIR, DSC, and XRPD) have
also reported similar data. They also found evidence of simple
inclusion complex formation (1:1 complexes) after interaction
of CBZ with HPβCD13,19,21,24−26,33 and HPγCD,13,33 although
always presenting smaller apparent K1:1 values compared with
those presented here. However, these discrepancies may be
due to the use of a different type of HPβCD compared with
the other studies (e.g., different manufactures of HPβCD
producing products with varying DS).
Contrary to the native CDs, analysis of the slope K1:1, CE, IS
for CBZ/HP-CDs (Table 1) does not suggest direct influence
of CD central cavity diameter on the increase of CBZ
solubilization/complexation.
2.2. Characterization of Solid-Phase Compositions.
The composition of solid phases resulting from the phase-
solubility studies (Section 2.1) was determined by FTIR
spectroscopy, DSC, and XRPD.
All techniques provided similar conclusions (see the
Supporting Information), and results were supportive of
phase-solubility experiments. The composition of the solid
phase can be predicted from the phase-solubility diagram type
and possibly by CD aggregation process (Table 2). This
basically originates form the inherent ability of native CD to
Table 1. Type of Profile, Apparent Stability Constant (K1:1),
CE and Maximum Increase (in Percentage) in Apparent
Solubility of CBZ per mM of CD (IS) in the Different
Aqueous CBZ/CD Complex Solutions at 25 °Ca
carbamazepine (CBZ)
CD typeb slope K1:1 (M
−1) CE IS (%)
αCD AL 0.006 8.9 0.006 0.97
βCD AL 0.348 840.5 0.53 56.4
γCD BS 0.441 1245.1 0.79 69.9
HPαCD AL 0.022 31.4 0.02 3.4
HPβCD AL 0.699 3299.5 2.33 110.1
HPγCD AL 0.189 369.0 0.23 31.5
aPhase-solubility diagrams built with actual CD concentrations
instead of theoretical CD concentrations only showed some
differences for the B-type diagrams (i.e., beyond the plateau region).
As their initial linear part (i.e., before the plateau region) showed
negligible changes, Higuchi−Connors classification could still be used.
bAL: linear phase-solubility diagram and BS: phase-solubility diagram
with linear initial increase, a plateau and a decreasing terminal
solubility.30
Table 2. Variation of Solid-Phase Composition with Phase-
Solubility Type Profile and CD Concentration
phase-solubility
profile solid phase’s composition
A-type highly soluble complexes remaining in solution.
only excess of pure drug can be detected in solid phase.
B-type content of solid phase will vary with CD concentration and
surplus amount of model drug.
region before plateau ≫ only pure model drug.
plateau region ≫ a mixture of pure drug and insoluble
complexes will be found.
post plateau ≫ will mostly consist on solid complex,
although it is not possible to exclude the presence of pure
drug (depending on the initial excess of drug added and
availability of CD in liquid phase at that stage).
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form insoluble complexes (resulting in B-type phase solubility
diagrams), a trait not found for typical randomly modified
CD’s (e.g., commercially available hydroxypropyl derivatives).
Here, their inability to form insoluble complexes most often
results in A-type diagrams in the concentration ranges studied.
2.3. Osmolality Measurements. Osmometry is a
colligative property that indicates the number of all osmotically
active molecules dissolved in the solvent and in our previous
research proved to be quite useful to detect native CDs
aggregates.34
In an attempt to detect/quantify CBZ/CD inclusion
complexes aggregates and also tracing possible changes in
the apparent solubility of the CD complexes as a consequence
of interaction with soluble CBZ, the osmometry method was
applied to liquid phases from the phase-solubility experiment
after careful separation of the liquid and solid phases.
The osmolality of freshly prepared CD aqueous solutions
(represented by lines) and CD solutions saturated with CBZ
(represented by symbols with lines) were plotted against CD
concentrations. We expect that total osmolality will remain
constant or become slightly higher in case of the formation of
soluble complexes. Total osmolality will be equal to osmolality
of CD plus the one obtained from increased apparent solubility
of CBZ (as CD is present in higher amount, usually this
possible osmolality increase is only visible for βCD
complexes). On the other hand, we will observe a decrease
in total osmolality in the case of systems that displayed phase-
solubility B-type, as from some region (beyond plateau)
precipitation of solid complex will decrease the particle
concentration in the solution.
2.3.1. Native CDs. Different trends in osmolality behavior
were registered for native CDs after interaction with CBZ,
depending on the sample phase-solubility type (Figure 3).
For CBZ/αCD liquid phases, almost no changes were
observed in osmolality from samples saturated with CBZ
(Figure 3a). This is in accordance with phase-solubility results
as the presented osmolality plot is typical from AL-type profiles.
In the case of CBZ/βCD, the presence of CBZ promotes a
small constant increase of the osmolality of the CD solutions
throughout the concentration range (Figure 3b).
Commonly, samples containing γCD show negative
deviations of osmolality from stock solutions trend, caused
by a decrease in particle concentration due to the precipitation
of poorly soluble CBZ/γCD complexes at a certain CD
concentration (Figure 3a). The BS-type profile nature of this
system justifies the appearance of CBZ/γCD osmolality
graphic that can be divided into three characteristic regions.
As saturation concentration for the complex is achieved with
relatively low γCD concentrations, the two first regions are
relatively short. First, we observe the linear region (until
∼0.006 M) where the CBZ/γCD complex contributes to the
increase of system osmolality because the osmolality of the
solution containing both CBZ and γCD is higher than that
observed for the γCD stock solution alone. This effect will
continue until the crossing point with the CD curve (second
region represented by a small plateau from ∼0.006 to 0.014
M) where the poorly soluble CBZ/γCD complex starts to form
and overall osmolality will remain almost unalterable. Then, we
enter on the last region for this system (beyond plateau region,
from ∼0.014 M), where precipitation of poorly soluble
complex stops because of unavailability of solid CBZ, and
adding more γCD will only increase the amount of free γCD in
solution. Because of this, the total osmolality of the system
starts to increase again, however, never reaching γCD stock
solution values (dot line in Figure 3a).
2.3.2. Hydroxypropylated Cyclodextrins. Similarly, to the
CBZ/αCD and CBZ/βCD systems (AL-type), also the
saturation of HP-CDs with CBZ did not provide any
significant change on system total osmolality (Figure 4). It is
typical for A-type profiles that throughout the CD concen-
tration range, the amount of osmotically active particles
remains the same or slightly higher in comparison with the
initial CD stock solution. The described behavior observed in
Figure 4 excludes the possibility of formation and precipitation
of CBZ/HP-CDs inclusion complexes.
Figure 3. (a) Changes of total osmolality for the prepared CBZ/αCD and CBZ/γCD systems during phase-solubility experiments (25 °C). (b)
Changes of total osmolality for the CBZ/βCD systems during phase-solubility experiments (25 °C). Symbols represent mean ± SD (n = 3).
Figure 4. Total osmolality changes for of the prepared CBZ/HP-CD
systems during phase-solubility experiments (25 °C). Symbols
represent mean ± SD (n = 3).
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Altogether, these observations corroborate phase-solubility
results for HP-CDs, where they displayed AL-type.
Osmometry proved to be a simple and reliable method to
determine phase-solubility profiles of the studied systems.
However and contrary to what we described for native CD
aqueous solutions,34 this method was not capable of detecting
CD aggregate formation and determine the possible modu-
lation of these inclusion complexes on the self-assembly
process of the CDs. The precipitation of inclusion complexes
(that occurs for B-type profiles) and the increase of the
systems osmolality due to increase of CBZ concentration
makes it difficult to interpret deviations that occur in total
osmolality of these systems (e.g., osmolality can decrease due
to precipitation of components, presence of aggregates, etc.).
2.4. Solubility of Native and HP Derivatives in the
CBZ Media. To find a plausible justification for the osmolality
depression observed in previous chapter, the possible effect of
CBZ on CD complexes solubility was accessed. Graphical
representations of added CD concentration against actual CD
concentration (CD concentration in liquid phase after
equilibrium) during phase-solubility studies are provided in
Figures 5 and 6. Bisectors (described by solid lines)
representing the theoretical situation where added CD
concentrations equals that in solution were also included in
the figures.
For CBZ/αCD and CBZ/βCD, no significant difference is
observed between added αCD/βCD concentration and the
concentration at the end of experiment (Figure 5).
A different behavior was observed for γCD where no
changes in added and actual CD concentration are observed
initially in the linear region diverting from the bisector after
approximately 0.014 M γCD (Figure 5a). After saturation
concentration of CBZ/γCD inclusion complex is achieved
(matching with the point of diversion from bisector), the
plateau region is reached and precipitation of the complex
(consequently also CD) takes place. When solid CBZ is no
longer available in the system, the additional amount of CD
provided will lead to its accumulation in liquid phase. This
phenomenon explains the increase in actual γCD concen-
tration visible in Figure 5a after the plateau region (from
∼0.037 M).
Figure 6 shows that CBZ, as expected by AL phase-solubility
profile, did not have any influence and changed the solubility
of HP-CDs over the phase-solubility experiment. This can be
explained by the formation of complexes with high aqueous
solubility.
2.5. Permeation Studies. For these experiments, two
representative CBZ/CD systems were selected: native γCD
and HPβCD. These represent two of the most promising
candidates for formulation of CBZ as they display the highest
CE, apparent K1:1 and IS of the studied CDs. Furthermore,
they represent two distinctly different phase-solubility profiles
(BS and AL-type, respectively) and are used in the
pharmaceutical field. Thus, it is important to achieve more
knowledge on the possible influence that guests and inclusion
complexes can have on the self-assembly behavior of these
CDs. Knowing more about how guests with different
physicochemical properties can modulate the solubility and
aggregation process of CDs complexes, we can try to disclose
driving factors that can promote or prevent the formation of
these structures.
This fits in one of the goals we set for this work, the
detection and quantification of CD aggregation in the selected
systems (through apparent cac values). From permeation
studies, the apparent cac cannot be defined as the
concentration where CDs start to assemble in larger structures
(CD aggregates) but rather the concentration at which the size
starts to be a hindering factor for free flow of CDs through the
membrane (i.e., the aggregates size becomes greater than the
molecular weight-cutoff (MWCO) pore size of the membrane
tested and the cac determined is thus dependent on the choice
of MWCO of the membrane).
2.5.1. Hydroxypropylated βCD. The potential effect of CBZ
on HPβCD aggregation behavior was estimated through Franz
diffusion cell permeability studies using liquid phases from
phase-solubility studies. For this group of experiments, 3.5−5
kDa membrane was used and the flux of HPβCD from CBZ/
HPβCD systems was determined. Afterward, the flux values
were plotted versus HPβCD concentration and a tangent line
Figure 5. Illustration of α- and γCD (a) and βCD (b) solubility in the prepared CBZ/CD systems. Symbols represent mean ± SD (n = 3).
Figure 6. Illustration of HP-CDs solubility in the prepared CBZ/HP-
CD systems. Symbols represent mean ± SD (n = 3).
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to the flux curve was drawn to determine the concentration
point from where the flux curve started to divert from linearity.
This estimated value corresponds to the apparent cac value for
this MWCO pore size membrane.
Sink conditions35 were fulfilled for this set of experiments
(both HPβCD and γCD) as donor phases did not register
significant volume changes (were always less than 0.1 mL), and
CD concentration in the end of permeability experiments
(donor phase) was always higher than 90% of initial
concentration.
In Figure 7, it is possible to observe the flux curves for
HPβCD aqueous solutions (filled squares) and for HPβCD
from CBZ/HPβCD liquid phases (open circles). The flux
behavior of HPβCD aqueous solutions was previously studied
by our group.36 Apparent cac value for this system with 3.5−5
kDa MWCO membrane (the same as for the present study)
was determined to be 11.8% (w/v). This means that until the
apparent cac value HPβCD and any formed aggregates
permeated freely through the membrane to the receptor
phase because they did not have a particle size hindering their
diffusion through the membrane pores. Knowing that the
molecular weight of HPβCD is approximately 1.36 kDa, we
could estimate from the apparent cac that the aggregates
consisted of approximately 3−4 HPβCD monomers at cac.
It is understandable from Figure 7 that no significant
difference could be found between HPβCD flux curves from
HPβCD solutions and HPβCD from CBZ/HPβCD. Apparent
cac values (for 3.5−5 kDa) for the CBZ/HPβCD systems was
estimated to ∼11.6% (w/v) which is similar to the one found
for pure HPβCD solutions. The presence of CBZ did not affect
or promote the formation of HPβCD aggregates with larger
sizes than the one that are naturally formed in HPβCD
aqueous solutions. Altogether, these results suggest that CBZ
did not affect the self-assembly process of HPβCD.
2.5.2. Native γCD. Similar to what is described above, the
flux curve of γCD from CBZ/γCD liquid phases was plotted
against actual γCD concentration and compared with the flux
curve from γCD aqueous solution (Figure 8). The apparent
cac value (3.5−5 kDa MWCO) for both systems was
calculated and used to study the possible effect of CBZ on
natural aggregation of γCD.
Small but significant differences are noticeable when the flux
curve for γCD in aqueous solution (filled squares) is compared
with the one from γCD from CBZ/γCD samples (Figure 8).
γCD flux in aqueous solution increased linearly until a
concentration of 4.2% (w/v) (apparent cac value for 3.5−5
kDa) after which a negative deviation probably due to the
formation of aggregates and increased in size of aggregates is
observed. Beyond this, γCD concentration aggregates are most
likely assembled in sizes larger than the membrane pore size
selected for this study, hindering the free flux of γCD from
donor to receptor phase. We can estimate that after 4.2% (w/
v) γCD (MW 1297 Da) solutions, we have aggregated
populations of trimers and/or tetramers.
Regarding γCD from CBZ/γCD system, we can observe that
flux values after a certain γCD concentration significantly
dropped in comparison to γCD in aqueous solution. This
observation was supported by a decrease in the apparent cac
value which was estimated to 2.5% (w/v). Until this value,
aggregates of γCD and CBZ/γCD complexes could be present
in the solution with a maximum size of dimers or trimers which
are not large enough to make size a permeation limiting factor.
After 2.5% (w/v) of γCD, the flux deviated from linearity as
CBZ started to promote the formation of larger structures with
sizes larger (more than 3 monomers) than the membrane pore
size used in this study (3.5−5 kDa).
The CBZ/γCD system displayed a BS-type diagram in the
phase-solubility studies, and it is interesting to note the
apparent cac value (for 3.5−5 kDa) and the γCD
concentration at which highest solubility of CBZ/γCD
complex coincides. This suggests that the BS-type profile and
decrease in apparent CBZ solubility after the plateau region
might be related to the aggregate formation of the complex
that starts to precipitate out of solution as solid crystalline
complexes after this concentration have been reached.
All the collected data strongly suggest that CBZ had an
influence on the promotion of γCD aggregates formation.
Similar results were reported in previous publication where
indomethacin37 and parabens15 proved to influence γCD
aggregation and modulate its permeation profile.
2.5.3. Influence of HPβCD and γCD on Permeation
Behavior of CBZ. In previous chapters (2.5.1 and 2.5.2), we
described the influence of CBZ on the permeability and
aggregation profile of HPβCD and γCD complexes. In the
present one, we want to investigate the opposite effect, that is,
how these two CDs may affect the permeability of CBZ.
Both CDs were capable of forming inclusion complexes with
CBZ and thus capable to increase CBZ flux when compared
with CBZ alone (in aqueous solution). Figure 9 exemplifies the
CBZ flux variation for CBZ/HPβCD samples (Figure 9a) and
Figure 7. Flux profile of HPβCD from HPβCD aqueous solution
(filled squares) and CBZ/HPβCD liquid phases (empty circles)
through 3.5−5 kDa MWCO semipermeable membrane.
Figure 8. Flux profile of γCD in aqueous γCD solution (filled
squares) and γCD from CBZ/γCD liquid phases (empty circles)
through 3.5−5 kDa MWCO semipermeable membrane.
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for CBZ/γCD samples (Figure 9b) versus its respective
measured CBZ concentration.
Previously, we proved using permeation data that CBZ was
not able to modify the natural HPβCD permeation profile and
to promote any influence over HPβCD aggregation. Through
evaluation of Figure 9a, we can see a linear increase of CBZ
flux with CBZ concentration (following Fick’s first law)
promoted by the CBZ/HPβCD compared with CBZ SE.
HPβCD is able to increase and facilitate the flux of CBZ
molecules from donor to receptor chamber (higher amount of
CBZ/HPβCD complexes led to increase of CBZ apparent
solubility).
Contrarily, CBZ flux from complexed CBZ/γCD did not
present a linear relation with γCD concentration (Figure 9b).
Also, here a possible correlation of phase-solubility type profile
(BS-type) with the CBZ flux profile (from CBZ/γCD system)
can be used to explain the peculiar shape presented. This flux
curve starts with two points with relatively high flux values
(0.03%/3.5 × 10−4 and 0.048%/4.5 × 10−4) corresponding to
the linear part of phase-solubility experiment for this system.
The presence of increasing amount of soluble CBZ/γCD
inclusion complexes with γCD concentration justifies the
increase of CBZ apparent water solubility, as well as the
observed flux linear increase. However, it stops as soon as
saturation concentration of complex is achieved. This point is
depicted in Figure 9b as the one presenting simultaneously
highest flux and also highest CBZ concentration (0.073%/6.1
× 10−4).
Afterward a region where CBZ concentration decreases (due
to the precipitation of CBZ/γCD complexes) and simulta-
neously the flux (increasing presence of γCD aggregates) with
increasing actual γCD concentration can be observed. The
points analyzed corresponded already to plateau region and
beyond. We know that γCD concentration in solution is stable
along plateau part and slowly starts to increase after it (the
amount of available γCD in the liquid phase at this stage will
depend on the solid CBZ added at the beginning of
experiment). If γCD would not affect permeability of CBZ
(other than facilitate it by increasing its solubility), we should
observe an overlapping with previously described CBZ flux
points. This means that samples with same CBZ concentration
should present same flux values, however, that did not happen
because those samples have also different amounts of γCD
which probably explains the peculiar shape flux curve
registered.
From the analysis of these results, it is possible to suggest
that when the γCD concentration is increased in solution,
more and larger aggregates were formed. These superstructures
might be the involved on the precipitation of inclusion
complexes and by a decrease of CBZ in liquid phase as a
consequence. Their presence in the donor phase might hamper
the diffusion of matter from donor to receptor phase leading to
the marked drop of CBZ flux shown in Figure 9b.
Our finding that formulations based on inclusion complexes
of CBZ/γCD providing similar concentrations of CBZ (but
using different amounts of γCD) can be produced with
different permeability capacities can be an advantage to the
pharmaceutical research field. It might be a useful tool
especially for ocular or dermal delivery as different types of
drug delivery systems can be produced just by using different
concentrations of γCD (or other native CDs) in the
formulation (Figure 10).
We can hypothesize that small amounts of γCD (until
plateau region) will allow the production of formulations with
fast permeation of components (mainly constitutes by
monomers and small aggregates). On the other hand,
formulating with higher γCD concentrations (over plateau
region and beyond), γCD and CBZ/γCD complex aggregates
with larger size and in higher number are formed. The
inclusion complex permeability will be slowed down and,
consequently, sustained-permeation delivery systems can be
produced.
Figure 9. Flux profile of CBZ from CBZ/HPβCD liquid phases (a) and of CBZ from CBZ/γCD liquid phases (b) through 3.5−5 kDa MWCO
semipermeable membrane.
Figure 10. Schematic representation of native and hydroxypropylated CDs (A) and CBZ (B). Adapted from ref 39.
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3. CONCLUSIONS
Several interesting conclusions could be made from this
experimental work. The phase-solubility data could be fitted to
a model based on simple 1:1 complex formation suggesting, as
previously presented by other authors, that CBZ formed 1:1
complexes with all tested CDs. This does not prove that 1:1
complexes are formed and are responsible for the appearance
(linearity) of the phase-solubility curves. It only signifies that
the data can be fitted to a model for complex formation based
on a simple 1:1 stoichiometry. The lowest apparent solubility
increase was obtained for αCD which almost did not interact
with CBZ because of small cavity size (although it displayed
AL-type), and for γCD which formed complexes with limited
water solubility (BS-type), CD cavity size of the native CDs
showed to be an important factor for the better solubilization
of the drug, increasing with increasing diameter (αCD ≪ βCD
< γCD).
Expectedly, hydroxypropylated CD derivatives also displayed
AL-type. Because of the larger applicable range of CD
concentrations, the solubility enhancement achieved for CBZ
can reach higher values than that of their correspondent parent
CDs.
HPβCD was the best solubilizer agent for CBZ forming the
complexes with highest solubility and was most stable (K1:1 =
3296.3 M−1 and CE = 2.3). γCD proved to be the best option
from native CDs to solubilize CBZ (K1:1 = 928.9 M
−1; CE =
0.66 and IS = 69.9%/mM).
Overall the solid-state characterization techniques, as well as
osmometry data, provided similar conclusions and were
supportive of liquid phase results (phase-solubility, osmolality,
and permeation studies). However, in this study, osmometry
was not capable to reveal any possible influences of CBZ and
its complexes on the aggregation behavior of the CDs (and
consequently to determine apparent cac values). Nevertheless,
osmometry is a fast and reliable method to corroborate or
determine phase-solubility profiles.
Permeation studies have shown to be an extremely useful
tool to study aggregation and permitted the calculation of
apparent cac values for both HPβCD and γCD systems.
CBZ did not affect or promote the self-assembly process of
HPβCD contrary to γCD where CBZ had a clear influence on
the formation of its aggregates.
HPβCD had a clear influence on the CBZ flux, increasing
linearly with CBZ concentration due to the increase of
complexes formed facilitating permeation of CBZ through the
membrane. For γCD, aggregates significantly changed the flux
of CBZ through the semipermeable membranes because
samples with similar CBZ concentration but with different
concentrations of γCD present completely different perme-
ation abilities as opposed to overlapping of flux curves (more
and larger aggregates were formed when γCD concentration
increased yielding lower permeability and consequently lower
overall flux).
4. MATERIALS AND METHODS
4.1. Materials. The native CDs (αCD, βCD, and γCD) as
well as 2-hydroxypropyl-βCD (HPβCD) DS 4.2 (MW 1380)
were kindly provided by Janssen Pharmaceutica (Beerse,
Belgium). 2-Hydroxypropyl-αCD (HPαCD) with degree of
substitution 3.6 (MW 1180) and 2-hydroxylpropyl-γCD
(HPγCD) DS 4.2 (MW 1540) were purchased from Wacker
Chemie (Burghausen, Germany). CBZ was also kindly
provided by Janssen Pharmaceutica (Beerse, Belgium). The
solvent used for analysis (acetonitrile) was of high-perform-
ance liquid chromatography (HPLC) grade and obtained from
Sigma-Aldrich (St. Louis, Missouri, USA). Milli-Q water
(Millipore, Billerica, MA) was used to prepare CD solutions
and mobile phases.
4.2. CD Solutions Preparation. Different aqueous CDs
stock solutions (taking into account the intrinsic solubility of
CD being tested) were prepared. To promote faster dissolution
of the CDs, sonication at elevated temperature was used (60
°C/60 min) after which solutions were allowed to cool to
room temperature. The test solutions were then prepared by
dilution of these stock solutions. The CD concentration range
depended on the specific CD.
4.3. Quantitative Determination of CD/CBZ. A reverse-
phase ultra-HPLC (UHPLC) system from Dionex Softron
GmbH (Germering, Germany) was used for the simultaneous
determination of CBZ and CDs. The Ultimate 3000 series
consisted of a LPG-3400SD pump with a built-in degasser, a
WPS-3000 autosampler, a TCC-3100 column compartment,
and a Corona ultra RS detector. Phenomenex Kinetex C18 150
× 4.60 mm 5 μm column with a matching HPLC Security
Guard (Phenomenex, Cheshire, UK) was used. Acetonitrile
and water (50:50) were the components of mobile phase. The
flow rate was set to 1.0 mL/min, and temperature of the
column was set to 30 °C. The injection volume was 10 μL.
Chromatograms were evaluated using ChromeleonR version
7.2 SR4 (ThermoFisher Scientific, MA, USA).
4.4. Phase-Solubility Experiments. Phase-solubility
profiles for the CBZ/CD systems were achieved using the
isothermal saturation method. Solid CBZ was added in excess
amount (that assure the formation of solid phase in
equilibrium stage) to each vial together with 3 mL of CD
solution of given concentration. This methodology was used
for all six CDs tested and was performed in triplicate.
The formed suspensions were kept at 25 °C under constant
stirring. After reaching equilibrium (48 h), the mixture was
centrifuged for 10 min/3000 rpm using Rotina 35R (Hetich
Zentrifugen, Germany). Liquid phases were filtered through a
0.45 μm Phenex-RC filter (Phenomenex, Cheshire, UK) and
then diluted with Milli-Q water prior to UHPLC analysis. Solid
phases were collected and dried in an oven at 35 °C for two
days.
The Higuchi and Connors30 method was used to classify the
phase-solubility profiles. The apparent stability constant (K1:1,
eq 1) and the CE (eq 2) were determined from the slope of
the linear phase-solubility diagrams plots of the total drug
solubility ([Dt]) versus total concentration of CD in liquid
phase ([CDliq]) in moles per liter
26
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where S0 is the intrinsic solubility of the CBZ.
The maximum increase (in percentage) in apparent
solubility of CBZ per mM of CD (increase in solubility, IS)
for each CBZ/CD system was determined as follows (eq 3)
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where CBZmax corresponds to highest solubility of complex
and CDmax corresponds to the actual concentration of CD
needed to achieve it (measured in the liquid phase at
equilibrium). This value was calculated and is valid for linear
part of phase-solubility diagrams.
4.5. Osmolality Measurements. Osmolality measure-
ments were used to evaluate the aggregation behavior of the
CBZ/CD systems. To determine the osmolality of liquid
phases, a freezing point osmometer OSMOMAT 30 (Gonotec
GmbH, Germany) was used. Calibration was performed with
three points: Milli-Q water and by saline standard of 300 or
400 mOsmol/kg NaCl/H2O (KNAUER, Germany) depending
on concentration range of analyzed samples. For this
procedure, only 50 μL of the sample was required. Samples
were measured immediately after filtration of liquid phases to
avoid possible precipitation of components during storage.
4.6. Permeation Studies. Unjacketed Franz diffusion cells
with diffusion area of 1.77 cm2 (SES GmbHAnalyse
systeme, Germany) were used to determine the possible
influence of CBZ on γCD and HPβCD apparent cac values
and the effect of these CDs on the capability of CBZ to
penetrate semipermeable membranes.
12 mL of Milli-Q autoclaved water (to remove dissolved air)
were used as receptor phase, while the donor phase consisted
in 2 mL of different liquid phases (from phase-solubility
experiments). In between the two compartments, a 3.5−5 kDa
MWCO semipermeable cellulose ester membrane (Biotech
CE, Spectrum Europe, Breda, NL) was placed. All permeability
experiments were carried out at room temperature under
continuous magnetic stirring (300 rpm) of receptor phase
(donor phase was unstirred).
Sampling was initiated after 1 h for γCD and 0.25 h for
HPβCD after which the amount of CBZ diffused into the
receptor phase was above the quantification limit. Samples
were withdrawn every 15 min hereafter at determined time
points: 60−120 min for γCD and from 15 to 75 min for
HPβCD, 150 μL of sample was collected from the receptor
phase and immediately replaced by equal volume of Milli-Q
water. UHPLC was used to simultaneously quantify CD and
CBZ. Steady-state flux (J) of the CBZ/CD was calculated from
the slope (dq/dt) of the linear regression relationship between
time (t) and the amount of CBZ and CD in receptor phase (eq
4)
J
q t
A
P C
d /d
app d= = · (4)
where A is the diffusion area (1.77 cm2), Papp is the apparent
permeability, and Cd is the total CBZ/CD concentration in the
donor phase.
To assure sink conditions, common guidelines were
followed, where both volume change and final concentration
of components in donor phases were assessed.35,38
The calculation of the apparent cac for 3.5−5 kDa (i.e.,
concentration from where aggregates size starts to be larger
than the studied pore size, leading to a deviation of ideal flux of
CDs through the membrane) was performed by drawing
tangent lines in the flux graphics (starting at low concen-
trations). The deviation point from where the flux started to
divert from linearity corresponded to apparent cac value.34
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